Global Tetanus Toxoid Vaccine Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com

The "Tetanus Toxoid Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The Tetanus Toxoid Vaccine Market is expected to register a CAGR of 4.8% during the forecast period.

Tetanus also known as lockjaw is a non-communicable serious disease caused by a bacterial toxin that affects the nervous system, leading to painful muscle contractions, particularly jaw and neck muscles. It is caused by Clostridium tetani (C tetani) which is found in human and animal feces, soil and street dust.

The bacteria enter the body through wounds. Some of the symptoms include lockjaws (paralysis of the jaw), muscle stiffness, back pain, difficulties in breathing and spasms. Most of all cases of tetanus occur in people who have never been vaccinated or in adults who haven't kept up with their 10-year booster shots. The different vaccines that include protection against tetanus are DTaP vaccine, DT vaccine, Tdap vaccine and Td vaccine.

Companies Mentioned

• Merck & Co. Inc
• GlaxoSmithKline Plc
• Sanofi (Sanofi Pasteur, Inc)
• Pfizer, Inc
• Bharat Biotech
• Astellas Pharma Inc
• Panacea Biotec Ltd
• BB - NCIPD Ltd
• PT Bio Farma
• Biological E Limited

Key Market Trends

Diphtheria, Tetanus, and Pertussis (DTaP) Vaccines Segment is Expected to Hold a Major Market Share in the Tetanus Toxoid Vaccine Market

• Diphtheria, Tetanus, and Pertussis (DTaP) vaccines segment holds a significant market share in the tetanus toxoid vaccine market and is anticipated to show a similar trend over the forecast period owing to growing government initiatives to eradicate these diseases.
• DTaP is a vaccine that helps in developing immunity against three deadly diseases caused by diphtheria, tetanus, and whooping cough (pertussis) in children younger than 7 years old.
• According to the World Health Organization (WHO), in 2017 worldwide 38,000 people died from tetanus. Around half (49%) were younger than five years old. Moreover, 77% of all deaths from tetanus, 29,500 lives lost, occur in South Asia and Sub-Saharan Africa. In addition, South Asia and Sub-Saharan Africa account for 82% of all tetanus cases globally.
• Low costs of the vaccine, increasing cases of tetanus and increasing availability in low resource economies like Africa are the key driving factors in the Diphtheria, Tetanus, and Pertussis (DTaP) vaccines segment.

North America is Expected to Hold a Significant Share in the Market

North America is expected to hold a major market share in the global tetanus toxoid vaccine market due to increasing cases of tetanus and diphtheria, and higher cost, high coverage, and adoption in this region. According to the Centers for Disease Control and Prevention (CDC), in 2017, a total of 33 tetanus cases and 2 deaths were reported in the United States.

Moreover, from 2009 through 2017, a total of 264 cases and 19 deaths from tetanus were reported. Sixty cases (23%) were in people with 65 years of age or older, 168 cases (64%) in people 20 to 64 years of age, and 36 cases (13%) were in younger than 20 years. All tetanus-related deaths occurred among patients greater than 55 years of age. Furthermore, increasing focus to control the incidence and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Assumptions

1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Cases of Tetanus and Diphtheria

4.2.2 Growing Research and Development Activities for New Vaccines

4.2.3 Increasing Government Initiatives Programs for Vaccination

4.3 Market Restraints

4.3.1 Side-Effects Associated with Toxoid Vaccine

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Vaccine Type

5.1.1 Diphtheria, Tetanus, and Pertussis (DTaP)

5.1.2 Diphtheria and Tetanus (DT)

5.1.3 Tetanus, Diphtheria, And Pertussis (Tdap)

5.1.4 Other Vaccines

5.2 By End User

5.2.1 Hospitals and Clinics

5.2.2 Other End Users

5.3 Geography

5.3.1 North America

5.3.1.1 United States

5.3.1.2 Canada

5.3.1.3 Mexico

5.3.2 Europe

5.3.2.1 Germany

5.3.2.2 United Kingdom

5.3.2.3 France

5.3.2.4 Italy

5.3.2.5 Spain

5.3.2.6 Rest of Europe

5.3.3 Asia-Pacific

5.3.3.1 China

5.3.3.2 Japan

5.3.3.3 India

5.3.3.4 Australia

5.3.3.5 South Korea

5.3.3.6 Rest of Asia-Pacific

5.3.4 Middle-East and Africa

5.3.4.1 GCC

5.3.4.2 South Africa

5.3.4.3 Rest of Middle-East and Africa

5.3.5 South America

5.3.5.1 Brazil

5.3.5.2 Argentina

5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/vdv0tv

View source version on businesswire.com: https://www.businesswire.com/news/home/20200814005369/en/